A Phase 1 safety study of GRNOPC1 in patients with neurologically complete, subacute, spinal cord injury
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2018
Price : $35 *
At a glance
- Drugs OPC 1 (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; First in man
- Sponsors Asterias Biotherapeutics
- 31 Jul 2018 Updated results from the 25 subjects (SCiStar study) and 5 subjects from this Phase 1 safety study are presented in an Asterias Biotherapeutics media release.
- 21 Mar 2017 Results published in an Asterias Biotherapeutics media release.
- 21 Jun 2016 According to an Asterias Biotherapeutics media release, the results of this trial will be presented at the 2016 International Society for Stem Cell Research (ISSCR) Annual Meeting.